[go: up one dir, main page]

PE20151890A1 - Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn - Google Patents

Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn

Info

Publication number
PE20151890A1
PE20151890A1 PE2015001214A PE2015001214A PE20151890A1 PE 20151890 A1 PE20151890 A1 PE 20151890A1 PE 2015001214 A PE2015001214 A PE 2015001214A PE 2015001214 A PE2015001214 A PE 2015001214A PE 20151890 A1 PE20151890 A1 PE 20151890A1
Authority
PE
Peru
Prior art keywords
pyridazine
disustituted
analogs
methods
conditions related
Prior art date
Application number
PE2015001214A
Other languages
English (en)
Inventor
Atwood Cheung
Donovan Noel Chin
Natalie Dales
Aleem Fazal
Moo Sung
John Kerrigan
Gary O'brien
Lei Shu
Robert Sun
Timothy Brian Hurley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151890A1 publication Critical patent/PE20151890A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referida a un compuesto derivado de piridazina de la formula I o una sal farmaceuticamente aceptable del mismo que actua como modulador de la actividad SNM(gen de sobrevivencia de neuronas motoras), un metodo para la elaboracion de los compuestos de la invencion. La presente invencion proporciona ademas una combinacion de agentes farmacologicamente activos y una composicion farmaceutica
PE2015001214A 2012-08-13 2013-08-13 Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn PE20151890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261682448P 2012-08-13 2012-08-13

Publications (1)

Publication Number Publication Date
PE20151890A1 true PE20151890A1 (es) 2016-01-13

Family

ID=49029227

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001214A PE20151890A1 (es) 2012-08-13 2013-08-13 Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE2020000186A PE20201165A1 (es) 2012-08-13 2013-08-13 Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020000186A PE20201165A1 (es) 2012-08-13 2013-08-13 Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn

Country Status (40)

Country Link
US (6) US8729263B2 (es)
EP (3) EP3564233B1 (es)
JP (1) JP6190883B2 (es)
KR (3) KR102368439B1 (es)
CN (1) CN104583196B (es)
AP (1) AP2015008242A0 (es)
AR (1) AR092108A1 (es)
BR (1) BR112015003004B1 (es)
CA (1) CA2880273A1 (es)
CL (1) CL2015000331A1 (es)
CR (1) CR20150078A (es)
CU (1) CU20150014A7 (es)
CY (1) CY1124882T1 (es)
DK (1) DK2885288T3 (es)
EA (1) EA032005B1 (es)
EC (1) ECSP15009862A (es)
ES (2) ES2902198T3 (es)
GT (1) GT201500030A (es)
HR (1) HRP20211957T1 (es)
HU (1) HUE057007T2 (es)
IL (1) IL237067B (es)
JO (1) JO3530B1 (es)
LT (1) LT2885288T (es)
MA (1) MA37834A1 (es)
MX (2) MX375731B (es)
MY (2) MY176488A (es)
NZ (1) NZ704738A (es)
PE (2) PE20151890A1 (es)
PH (1) PH12015500236B1 (es)
PL (1) PL2885288T3 (es)
PT (1) PT2885288T (es)
RS (1) RS62692B1 (es)
SG (2) SG11201500507UA (es)
SI (1) SI2885288T1 (es)
TN (1) TN2015000038A1 (es)
TW (1) TWI635083B (es)
UA (1) UA114726C2 (es)
UY (1) UY34974A (es)
WO (1) WO2014028459A1 (es)
ZA (1) ZA201500531B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
KR20210130843A (ko) * 2013-07-31 2021-11-01 노파르티스 아게 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
SG11201702682PA (en) 2014-10-03 2017-04-27 Cold Spring Harbor Lab Targeted augmentation of nuclear gene output
CA2966423C (en) * 2014-10-31 2023-10-24 The General Hospital Corporation Potent gamma-secretase modulators
JP6884102B2 (ja) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
EP3053577A1 (en) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
US10196639B2 (en) 2015-10-09 2019-02-05 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
JP7049248B2 (ja) 2015-12-14 2022-04-06 コールド スプリング ハーバー ラボラトリー 常染色体優性精神遅滞－５とドラベ症候群の処置のためのアンチセンスオリゴマー
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CA3012700A1 (en) * 2016-02-01 2017-08-10 Arrakis Therapeutics, Inc. Compounds and methods of treating rna-mediated diseases
EP3419981A4 (en) 2016-02-23 2019-09-18 Indiana University Research & Technology Corporation COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
WO2018232039A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
KR102636383B1 (ko) * 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
EP3700570B1 (en) 2017-10-23 2025-01-08 Stoke Therapeutics, Inc. Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
SG11202003664TA (en) 2017-11-30 2020-05-28 Arrakis Therapeutics Inc Nucleic acid-binding photoprobes and uses thereof
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019199972A1 (en) 2018-04-10 2019-10-17 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
SI3814357T1 (sl) 2018-06-27 2024-09-30 Ptc Therapeutics, Inc. Heterociklične in heteroarilne spojine za zdravljenje Huntingtonove bolezni
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US20210179586A1 (en) 2018-09-07 2021-06-17 Teva Pharmaceuticals International Gmbh Solid state forms of branaplam and their preparation
JP2022513976A (ja) * 2018-12-21 2022-02-09 ノバルティス アーゲー ブラナプラムの経口製剤
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR20210135240A (ko) * 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920928A4 (en) * 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
EP4219466A1 (en) * 2019-05-13 2023-08-02 PTC Therapeutics, Inc. Compunds for treating huntington's disease
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
WO2021174163A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Fused bicyclic compounds useful for modulating nucleic acid splicing
US20230148184A1 (en) 2020-02-28 2023-05-11 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CA3169667A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
EP4110775A1 (en) 2020-02-28 2023-01-04 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
CN115551593A (zh) 2020-04-08 2022-12-30 雷密克斯医疗公司 用于调节剪接的化合物和方法
WO2021207530A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
BR112022020147A2 (pt) * 2020-04-09 2022-11-22 Ptc Therapeutics Inc Compostos para tratar a doença de huntington
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc opa1 antisense oligomers for the treatment of conditions and diseases
EP4149937A1 (en) 2020-05-13 2023-03-22 CHDI Foundation, Inc. Htt modulators for treating huntington's disease
TW202216671A (zh) 2020-06-25 2022-05-01 瑞士商諾華公司 １，４—二取代的嗒𠯤化合物之製造方法
MX2023000167A (es) 2020-07-02 2023-05-03 Remix Therapeutics Inc Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas.
AU2021299515A1 (en) 2020-07-02 2023-02-02 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
CA3230256A1 (en) 2021-08-30 2023-03-09 Dominic Reynolds Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240400584A1 (en) 2021-08-30 2024-12-05 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202319047A (zh) 2021-08-30 2023-05-16 美商雷密克斯醫療公司 調節剪接之化合物及用途
TW202330552A (zh) 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
TW202333689A (zh) 2021-10-13 2023-09-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
CA3238090A1 (en) 2021-11-17 2023-05-25 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
CN118843625A (zh) * 2021-11-22 2024-10-25 亚根达医疗公司 杂环取代的1,3,4-噻二唑和哒嗪化合物及其使用方法
US20250092065A1 (en) 2022-01-05 2025-03-20 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2023133229A2 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202346305A (zh) 2022-01-05 2023-12-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药（上海）有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN121443613A (zh) * 2024-05-30 2026-01-30 纽欧申医药(上海)有限公司 哒嗪环类化合物、其药物组合物及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2516040C2 (de) 1974-06-10 1984-12-20 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2427943C2 (de) 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FI962184L (fi) 1993-11-24 1996-05-23 Du Pont Merck Pharma Uusia isoksatsoliini- ja isoksatsolifibrinogeenireseptoriantagonisteja
JP2003522767A (ja) 2000-02-11 2003-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド ニューロン損傷の処置または予防のためのピペラジンおよびピペリジン誘導体
EP1133993A1 (en) 2000-03-10 2001-09-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
AU7527901A (en) 2000-06-07 2001-12-17 Vertex Pharma Caspase inhibitors and uses thereof
US6376508B1 (en) 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
AR041508A1 (es) 2002-08-09 2005-05-18 Astra Ab Compuestos con actividad en los receptores de glutamato metabotropicos
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
DK1562945T3 (da) 2002-11-11 2007-03-05 Neurosearch As Hidtil ukendte diazebicykliske biarylderivater
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
CN1812981A (zh) 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
JP2007502773A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
FR2868780B1 (fr) 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
US20100234409A1 (en) 2004-05-21 2010-09-16 Lihu Yang Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
AU2005283085B2 (en) 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP1637141B1 (en) 2004-09-21 2011-11-16 Trobio AB Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease
ES2400689T3 (es) 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
AU2005298693A1 (en) * 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
CN103110635A (zh) * 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
KR20080079250A (ko) * 2005-12-06 2008-08-29 뉴로서치 에이/에스 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
TW200813051A (en) 2006-05-08 2008-03-16 Neurogen Corp Substituted azaspiro derivatives
DK2018380T3 (da) * 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0704394D0 (en) 2007-03-07 2007-04-11 Senexis Ltd Compounds
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
MX2010005298A (es) 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
NZ703814A (en) 2008-02-28 2016-06-24 Vertex Pharma Heteroaryl derivatives as cftr modulators
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
EP2288609A2 (en) 2008-06-10 2011-03-02 NeuroSearch A/S Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
EP2350048A2 (en) 2008-10-16 2011-08-03 Schering Corporation Azine derivatives and methods of use thereof
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
CN102596962A (zh) 2009-09-10 2012-07-18 弗·哈夫曼-拉罗切有限公司 Jak抑制剂
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
US8673928B2 (en) 2009-11-18 2014-03-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US20130096160A1 (en) 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2606022A2 (en) 2010-08-16 2013-06-26 Santhera Pharmaceuticals (Schweiz) AG Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2012127393A1 (en) 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
UA113223C2 (xx) 2012-08-13 2016-12-26 Арилетинілпіримідини
BR112015011497B1 (pt) 2012-11-27 2023-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Composto, e, formulação farmacêutica
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
KR20210130843A (ko) 2013-07-31 2021-11-01 노파르티스 아게 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
PE20201165A1 (es) 2020-10-28
ECSP15009862A (es) 2019-03-29
CL2015000331A1 (es) 2015-08-28
MX375731B (es) 2025-03-06
US10195196B2 (en) 2019-02-05
KR102172911B1 (ko) 2020-11-03
MY176488A (en) 2020-08-12
HK1207862A1 (en) 2016-02-12
DK2885288T3 (da) 2022-01-10
PL2885288T3 (pl) 2022-02-07
UA114726C2 (uk) 2017-07-25
RS62692B1 (sr) 2022-01-31
CR20150078A (es) 2015-05-29
US20220387428A1 (en) 2022-12-08
HUE057007T2 (hu) 2022-04-28
MY174339A (en) 2020-04-09
SG10201701123QA (en) 2017-04-27
JP6190883B2 (ja) 2017-08-30
CN104583196B (zh) 2016-10-12
KR20220029764A (ko) 2022-03-08
EP4101849A1 (en) 2022-12-14
PH12015500236B1 (en) 2016-02-03
KR20200126016A (ko) 2020-11-05
EP3564233A1 (en) 2019-11-06
ES2950450T3 (es) 2023-10-10
HRP20211957T1 (hr) 2022-03-18
US8729263B2 (en) 2014-05-20
CU20150014A7 (es) 2015-07-30
US9545404B2 (en) 2017-01-17
ES2902198T3 (es) 2022-03-25
TN2015000038A1 (en) 2016-06-29
PT2885288T (pt) 2022-01-06
MX2020010151A (es) 2021-01-15
TW201412721A (zh) 2014-04-01
KR20150041655A (ko) 2015-04-16
LT2885288T (lt) 2021-12-27
AP2015008242A0 (en) 2015-01-31
JP2015524842A (ja) 2015-08-27
WO2014028459A1 (en) 2014-02-20
BR112015003004A2 (pt) 2017-07-04
US20140213570A1 (en) 2014-07-31
EA032005B1 (ru) 2019-03-29
MX2015001892A (es) 2015-05-07
AU2013302859A1 (en) 2015-02-19
CA2880273A1 (en) 2014-02-20
GT201500030A (es) 2017-09-28
US20190358226A1 (en) 2019-11-28
EA201590371A1 (ru) 2015-06-30
SG11201500507UA (en) 2015-03-30
EP2885288A1 (en) 2015-06-24
KR102368439B1 (ko) 2022-02-28
BR112015003004B1 (pt) 2020-09-24
AU2013302859B2 (en) 2016-07-14
US20140051672A1 (en) 2014-02-20
CY1124882T1 (el) 2022-11-25
IL237067B (en) 2019-03-31
US20170290828A1 (en) 2017-10-12
US11229648B2 (en) 2022-01-25
CN104583196A (zh) 2015-04-29
TWI635083B (zh) 2018-09-11
PH12015500236A1 (en) 2015-03-30
MA37834A1 (fr) 2018-09-28
NZ704738A (en) 2016-02-26
SI2885288T1 (sl) 2022-01-31
US10758533B2 (en) 2020-09-01
EP3564233B1 (en) 2023-05-03
US20200345732A1 (en) 2020-11-05
JO3530B1 (ar) 2020-07-05
UY34974A (es) 2014-03-31
ZA201500531B (en) 2018-11-28
EP2885288B1 (en) 2021-10-06
AR092108A1 (es) 2015-03-25

Similar Documents

Publication Publication Date Title
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
CU20130094A7 (es) Moduladores de la vía del complemento
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
MX349712B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos.
ECSP14013230A (es) Compuesto de ciclopropanoamina
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
UY33815A (es) Composiciones y métodos para modular el fxr
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
PE20150887A1 (es) Compuestos de benceno sustituidos
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina